Key statistics
On Tuesday, Organon & Co (1OGN:MIL) closed at 7.06, 29.90% above the 52 week low of 5.44 set on Nov 05, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 7.06 |
|---|---|
| High | 7.06 |
| Low | 7.06 |
| Bid | -- |
| Offer | -- |
| Previous close | 6.98 |
| Average volume | 246.20 |
|---|---|
| Shares outstanding | 259.98m |
| Free float | 259.32m |
| P/E (TTM) | 4.21 |
| Market cap | 2.11bn USD |
| EPS (TTM) | 1.92 USD |
| Annual div (ADY) | 0.0693 EUR |
|---|---|
| Annual div yield (ADY) | 0.99% |
| Div ex-date | Nov 19 2025 |
| Div pay-date | Dec 11 2025 |
Data delayed at least 15 minutes, as of Feb 03 2026 11:13 GMT.
More ▼
Press releases
- Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
- Organon Completes Divestiture of JADA® System to Laborie
- Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
- Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
- Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
- Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
- Organon Reports Results for the Third Quarter Ended September 30, 2025
More ▼
